Cargando…

Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study

BACKGROUND AND AIM: This study aimed to clarify the efficacy and safety of oral semaglutide treatment in patients with non‐alcoholic fatty liver disease (NAFLD) complicated by type 2 diabetes mellitus (T2DM). METHODS: This was a single‐arm, open‐label pilot study. Sixteen patients with NAFLD who rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arai, Taeang, Atsukawa, Masanori, Tsubota, Akihito, Ono, Hirotaka, Kawano, Tadamichi, Yoshida, Yuji, Okubo, Tomomi, Hayama, Korenobu, Nakagawa‐Iwashita, Ai, Itokawa, Norio, Kondo, Chisa, Nagao, Mototsugu, Iwakiri, Katsuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260206/ https://www.ncbi.nlm.nih.gov/pubmed/35822119 http://dx.doi.org/10.1002/jgh3.12780

Ejemplares similares

Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial
por: Okubo, Tomomi, et al.
Publicado: (2021)

How do the 2022 European Society of Cardiology/European Respiratory Society guidelines modify the diagnosis of portopulmonary hypertension in patients with cirrhosis complicated by portal hypertension? A post hoc analysis
por: Atsukawa, Masanori, et al.
Publicado: (2023)

Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease
por: Arai, Taeang, et al.
Publicado: (2021)

Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
por: Arai, Taeang, et al.
Publicado: (2021)

A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C
por: Yoshida, Yuji, et al.
Publicado: (2023)

Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus
por: Arai, Taeang, et al.
Publicado: (2022)

Factors Associated with Hepatitis B Surface Antigen Kinetics and Responses in Pegylated Interferon Alpha-2a Monotherapy for Patients with Chronic Hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2021)

Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease
por: Arai, Taeang, et al.
Publicado: (2019)

Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease
por: Kawano, Tadamichi, et al.
Publicado: (2022)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2020)

Influencing factors on serum 25-hydroxyvitamin D(3) levels in Japanese chronic hepatitis C patients
por: Atsukawa, Masanori, et al.
Publicado: (2015)

Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study
por: Atsukawa, Masanori, et al.
Publicado: (2013)

A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C
por: Atsukawa, Masanori, et al.
Publicado: (2021)

Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression
por: Masu, Takushi, et al.
Publicado: (2018)

Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C
por: Kato, Keizo, et al.
Publicado: (2019)

Mac‐2‐binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C
por: Kawata, Kazuhito, et al.
Publicado: (2022)

Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment
por: Okubo, Hironao, et al.
Publicado: (2022)

Type III procollagen peptide level can indicate liver dysfunction associated with volume overload in acute heart failure
por: Shirakabe, Akihiro, et al.
Publicado: (2022)

Relationship between response to lusutrombopag and splenic volume
por: Uojima, Haruki, et al.
Publicado: (2018)

Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study
por: Atsukawa, Masanori, et al.
Publicado: (2020)

Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease
por: Kumagai, Erina, et al.
Publicado: (2016)

Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan
por: Toyoda, Hidenori, et al.
Publicado: (2019)

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

The Risk of Cirrhosis and Its Complications Based on PNPLA3 rs738409 G Allele Frequency
por: Shao, Xue, et al.
Publicado: (2022)

Usefulness of autotaxin for the complications of liver cirrhosis
por: Shao, Xue, et al.
Publicado: (2020)

Increased Frequency of Dysfunctional Siglec-7(−)CD57(+)PD-1(+) Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease
por: Sakamoto, Yuzuru, et al.
Publicado: (2021)

Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease
por: Shoji, Hirotaka, et al.
Publicado: (2016)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2019)

Intravenous injection of neural progenitor cells facilitates angiogenesis after cerebral ischemia
por: Moriyama, Yoshiyuki, et al.
Publicado: (2013)

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
por: Tada, Toshifumi, et al.
Publicado: (2021)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Semaglutide for type 2 diabetes
Publicado: (2020)

Semaglutide-associated bullous pemphigoid
por: Burruss, Clayton P., et al.
Publicado: (2021)

Semaglutide-eye-catching results
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sgh00ge1v7nhhbupi91ggvu0ot